Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
8.23
-0.46 (-5.29%)
Nov 18, 2026, 4:00 PM EST - Market closed
Enanta Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Enanta Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $21.83. The average 1-year stock price forecast is 165.25% higher than the current stock price, while the lowest is $19 (+130.86%) and the highest is $32 (+288.82%).
Price Target: $21.83 (+165.25%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Enanta Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $20 | Buy | Reiterates | $20 | +143.01% | Nov 17, 2026 |
Financial Forecast
Revenue This Year
64.09M
from 63.00M
Increased by 1.73%
Revenue Next Year
86.39M
from 64.09M
Increased by 34.79%
EPS This Year
-3.19
from -2.35
EPS Next Year
-2.27
from -3.19
EPS and Forward PE are based on non-GAAP adjusted numbers.